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Introduction
Octreotide is an analog of the natural somatostatin with 
high binding affinity for the SSTR2 and moderate binding 
to SSTR5 receptor, but with longer half-life. Hypothalamic 
hormones growth-hormone releasing hormone GHRH, gut 
hormone Ghrelin (stimulating) and somatostatin (inhibit-
ing) are key players in the regulation of GH synthesis, basal 
and pulsatile secretion in physiology. Octreotide was intro-
duced for the treatment of acromegaly in the 80 s. Initially, 
only short acting subcutaneous preparation were available 
requiring a three-daily injection regimen but in later stage 
an intramuscular depot preparation using microspheres was 
introduced, facilitating the use of the drug. Somatostatin 
and its analogs, i.e. octreotide and lanreotide, strongly sup-
press GH release in healthy controls and in patients with 
acromegaly.
Somatostatin analogs are first line medical treatment 
of acromegaly [1]. The long-term efficacy and safety have 
been evaluated in landmark studies, open label studies and 
summarized in numerous reviews, with 40–60% of patients 
achieving normalization of predefined GH and IGF-I tar-
gets reflecting a generally accepted level of control [2]. A 
significant proportion of adenomas show a variable degree 
of adenoma shrinkage, and during long-term somatosta-
tin analog treatment tumor growth is rarely observed. The 
safety profile of octreotide and other somatostatin analogs 
(SRLs) is fairly good, with mainly side effects that are a 
result of the selective activation of the receptors, that are 
also present in the GI system, i.e. bile stones, mild effects 
on glucose metabolism and gut motility, and furthermore 
local injection site related side effects.
The chance to achieve control is mainly dependent on 
the SSTR receptor status of the adenoma, and somewhat on 
the height of pretreatment GH levels. Other factors include 
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young age, large tumors, and certain MRI and pathological 
characteristics (hyperintensity on T2 weighted imaging and 
sparse granularity) [3]. Usually there is a variation in SRLs 
responsiveness within a continuous spectrum, the vast 
majority being either good or partial responsive to SRLs. 
This is exemplified for example in studies evaluating single 
doses of octreotide, i.e. octreotide tests [4]. Therefore also 
trial design, i.e. which patients are included (preselection 
on octreotide sensitivity), and criteria that define remission, 
are important factors that influence differences in reported 
remission rates of individual studies [5]. There is only a 
small subset of adenomas that is truly SRL resistant, usu-
ally because SSTR2 expression is lacking or low. Pasire-
otide, an SRL with increased affinity for SSTR5 and other 
SSTRs may have additive values over octreotide or lanreo-
tide in these situations.
Oral octreotide
Orally ingested octreotide fails to achieve therapeutic drug 
levels following absorption in the jejunum, due to the intes-
tinal barrier, only very low concentrations are measured. In 
early development of octreotide some, but too low and very 
variable, enteral absorption was reported and strategies to 
improve enteral absorption have not been successful up to 
now [6, 7]. The oral route has regained new interest with 
the introduction of the TPE technology, a transient permea-
bility enhancer (TPE) consisting of among others medium-
chain free fatty acids, sodium caprylate, inert excipients. 
Octreotide is encapsulated in an enteric coating, preventing 
breakdown before reaching the small intestine. The TPE is 
able to facilitate absorption of drug molecules and the com-
bination with octreotide is the first proof of concept study. 
Due to transient opening of intestinal epithelial tight junc-
tions drug molecules, as octreotide can traverse the tight 
junctions resulting in improved absorption, but absorption 
is dependent on molecular size. The current literature on 
this investigational drug from the first preclinical to the fin-
ished Phase III trial and a recent review on new therapeu-
tic agents will be summarized in this review. The drug is 
not yet approved for use and a new Phase III study is cur-
rently being conducted (clinical trials.gov: MPOWERED, 
NCT02685709).
Preclinical studies
Pharmacokinetic/ dynamic studies in rats and primates 
demonstrated a comparable pattern of octreotide drug levels 
between ingestion of oral octreotide capsule and sc octreo-
tide injection [8]. Both modes of delivery show a rapid and 
sustained (complete) suppression of GH concentrations 
for several hours. Safety studies in cynomolgus monkeys 
showed no toxic effects on organs and a comparable profile 
of oral octreotide capsules and subcutaneous injection. The 
gastrointestinal mucosa and epithelium was not affected.
Using fluorescent tracers in a rat model the effect of 
TPE on tight junctions is visualized and these experiments 
illustrate the mechanism of action of TPE. There is a tran-
sient reorganisation of the cytoskeleton for 1–2  h, with 
normalization afterwards. The molecular size in relation 
to absorption was assessed with dextran at several molec-
ular weights, with best absorption present with smallest 
dextrans (4 kDa). Larger dextrans (40–70 kDa) were only 
minimally absorbed, limiting the risk of internalization 
of intestinal pathogens and immunoglobulins. The short 
action and selectivity with respect to size are two important 
aspects to consider with respect to safety [8].
Phase I study
Single dose studies were conducted in 75 healthy volun-
teers using doses of 3, 10, 20 mg oral octreotide and 100 µg 
sc injection. There was a dose–response effect of the 3 dif-
ferent doses on plasma octreotide levels with PK parame-
ters proportional to the oral dose administered. Levels were 
detectable after 30  min of ingestion. Capsules of 20  mg 
and sc injection of 100 µg provide comparable plasma con-
centrations. After a 20 mg capsule levels peaked at 2.7 h, 
somewhat later than sc injection, with therapeutic levels 
upto 8  h. It was concluded that a two daily dose scheme 
would suffice. There is a significant interference with food 
intake as well as with proton pump inhibitors resulting 
in decreased bioavailability. Oral octreotide was able to 
suppress low basal GH secretion in healthy controls and 
strongly inhibited the peak GH elicited by GHRH-arginine 
stimulation from 50 to 10 ng/ml as well as suppressed the 
GH (AUC). Safety profile was comparable except for the 
lack of injection site related discomfort [9].
Phase III study
In a baseline-controlled open-label, multicentre Phase III 
study 155 patients were enrolled who were treated with 
stable doses (>3  m) of injectable SRL treatment and had 
sensitivity to octreotide as evidenced by full or partial bio-
chemical control (IGF < 1.3 ULN, GH < 2, 5  ug/L) [10]. 
The main goal of the trial was to show maintenance of 
control of GH and IGF-I baseline levels during treatment 
with oral octreotide capsule treatment. Four weeks after a 
last regular injection, patients were switched to oral octreo-
tide 40 mg (20 mg twice daily, >1 h before and >2 h after 
a meal). In the titration phase, patients were titrated up to 
80  mg daily if necessary to maintain GH and IGF-I lev-
els. Once stable, patients entered the maintenance phase 
with fixed doses continued to the end of the core study at 7 
months. The core study period was followed by a voluntary 
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extension phase of 6 months, resulting in a period of 13 
months of stable drug treatment. 86% percent of patients 
elected to continue with this extension phase. The modi-
fied intention to treat group (cohort with at least one effi-
cacy measure on capsules, mITT) showed maintenance of 
biochemical response (i.e. IGF-I < 1.3 ULN and GH < 2.5 
µg/L) in 65% of patients at end of core treatment and 62% 
at end of extension period. 85% of patients that could enter 
the fixed dose phase sustained response upto 13 months. 
Both in the mITT and the fixed dose populations, in the 
presence of unchanged IGF-I levels GH levels showed a 
profound suppression during oral octreotide, throughout 
the entire study period.
Clinical control of acromegaly related symptoms (head-
ache, asthenia, perspiration, swelling of extremities and 
joint pain) improved during the trial. Despite biochemical 
partial or full biochemical control baseline symptoms were 
present in 81% of patients on regular SRL injectables. By 
the end of the trial the severity of symptoms had decreased 
from baseline: 26% maintained, 54% improved the symp-
tom severity score. Also the proportion of subjects with at 
least one, two, or three acromegaly symptoms decreased 
from 79, 63, and 45%, respectively, at baseline on injecta-
bles to 68, 48, and 31% at the end of study during treatment 
with oral octreotide capsules. There is only partial correla-
tion with IGF-I levels or IGF-I control and symptoms [11].
Adverse events were compatible with the known side 
effect profile of octreotide or related to the disease. Most 
common side effects were gastrointestinal (nausea and 
diarrhoea), neurological (headache) and musculoskeletal 
(arthralgia) and observed in the earlier treatment period, 
resolving with continued treatment. Ten patients discon-
tinued because of GI side effects, 21 patients sustained a 
serious adverse event, and two patients died during the trial 
supposedly unrelated to study drug.
Detailed analysis of factors influencing (non)-respon-
siveness on octreotide capsules in this cohort of patients 
previously controlled on injectables was not included in the 
phase III study paper, however, uptonow some additional 
exploratory analysis have been performed and these have 
been published as meeting abstracts.
In general, octreotide sensitivity is mainly determined 
by somatostatin receptor subtype status of the tumor, and 
achievement of defined biochemical control criteria are 
dependent on this status, and also the disease activity 
(height of GH and IGF-I levels) and drug levels. There are 
as yet no clues that these factors are different for oral octre-
otide or injectables.
Mode of delivery specific issues for the oral route 
related to non-responsiveness are likewise, compliance 
and insufficient drug absorption. In the trial, these issues 
were vigorously monitored and instructions were given to 
prevent interaction with food and drugs. In the trial a sub-
set of patients had a PK analysis, confirming that a two 
daily dosing regimen provides therapeutic drug levels. It 
is of note that GH was evaluated just after oral octreotide 
capsule intake, and GH levels were firmly suppressed and 
so drug absorption was adequate. Firm GH suppression, 
suggestive for adequate octreotide absorption, was also 
present in non-responders, which was based on IGF-I cri-
terion in the majority of non-responders. The duration of 
GH suppression following ingestion was not evaluated.
Theoretically, trial specific issues to explain non-
responsiveness to some extent could be the trial design 
and the single time point and timing of GH curve used 
to classify patients. These factors are not unique to this 
specific trial. The baseline controlled trial without with-
drawal period to wean injectables did not allow further 
dose increase once a patient had entered the maintenance 
phase. Since the carry over effect of injectables may last 
for many weeks, it cannot be fully excluded that some of 
the non-responders on the low and medium oral octreo-
tide doses would have been responders at higher doses. 
Hormone levels fluctuate from time to time, and espe-
cially in patients with levels just around the cut-off level 
evaluation by single time point may influence the classifi-
cation of responder and (non) responder both at entry and 
at end of trial.
Factors influencing the response to oral octreotide was 
assessed in an exploratory analysis, presented at the meet-
ing of the Endocrine Society in 2015. Baseline biochemi-
cal control on injectable SRLs (IGF-I < 1 and GH < 2.5) 
and use of low to mid dose SRL injectables predicted 
subsequent favorable response to oral octreotide cap-
sules, i.e. 84.5% (49 of 58 subjects) [12]. The dose of oral 
octreotide required was related to baseline SRL dose. It is 
of note that some (24%) of patients that were classified at 
non-responder at baseline on injectables were responders 
at the end of the study on oral octreotide.
The GH criteria was met in the vast majority of 
patients on oral octreotide and non-responsive was 
mainly based on a failure to meet the IGF-I criterion. 
Although discrepancies in GH and IGF-I have been also 
described with injectables, this appears to be somewhat 
more pronounced during oral octreotide. Potential expla-
nations are variable (duration of) suppression of GH pul-
satility, particular during troughs of drug concentrations 
of both capsules (end of daily dose) and injections (and 
of monthly injection) and direct action of octreotide on 
the liver IGF-I production. Further experience with oral 
capsules need to clarify whether this differential effects 
of GH and IGF-I suppression are confirmed and whether 
these factors are of clinical relevance.
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Potential place of oral octreotide in the treatment 
of acromegaly
At present oral octreotide capsules are an investigational 
drug, therefore the place in the treatment algorithm is 
hypothetical. Any differences between oral versus long-act-
ing injectable SRLs are related to the administration route, 
frequency and the different pharmacokinetic profile, and 
both options may have advantages and disadvantages and 
will have individual preferences. However, both act on the 
same SSTR receptor subtypes and since sensitivity to the 
drug will be mainly dependent on the receptor status and 
post receptor machinery and will therefore be more or less 
comparable, once therapeutic drug levels are achieved [3]. 
According to the results of the phase III study the majority 
of patients controlled on injectables—except for the small 
subset that experienced unacceptable side effects (10%) 
and patients that loose control possibly due to inadequate 
drug levels, low absorption, compliance etc. (35%)—can be 
treated with either injectables or oral capsules and advan-
tages and preferences would need to be carefully weighed 
to the personal situation, once both drug delivery methods 
would be available.
In a PRO study the patient perspective on use of injecta-
bles was explored in the chronically treated cohort of acro-
megaly patients [13]. Many patients have active symptoms 
while on injectables and some reported aggravation of 
symptomatology towards the end of the injection interval, 
so called wear off phenomenon. Burden due to injection 
related symptoms were reported, although the majority of 
patients is satisfied with current treatment with injectables. 
Avoiding injections and better symptom control are two 
reported unmet needs.
The two daily regimen of capsules requires ongoing 
and strict compliance of patients, which needs ongoing 
effort, and needs to be monitored probably more inten-
sively than treatment with injectables to prevent episodes 
of uncontrolled acromegaly. On the other hand it will pro-
vide patients tools to prevent the experienced instability 
in control during monthly injections (wear off effect), and 
may be easier to titrate and withdraw than the very long-
acting injections requiring months to achieve a plateau and 
to withdraw.
The profound suppression of GH observed in oral octre-
otide that may indicate a different dynamic of the GHIGF-
I axis is a very interesting observation, requiring further 
study to understand consequences at tissue level and recep-
tor status. It could be related to the observed improvement 
in symptoms but need further investigations to draw con-
clusions. There are no published data on the effect of octre-
otide capsules on tumor shrinkage.
The improved symptom status during the trial needs to 
be interpreted with caution, because it was an open label 
study and close monitoring of the patients during the trial 
may bias this observation. The correlation between symp-
toms and biochemical status is not straightforward, but 
symptoms are a very relevant clinical endpoint, although 
difficult to measure because of the fact that symptoms may 
be only partly reversible and are likely multifactorial.
It is important to note that also any chosen biochemi-
cal endpoints of any acromegaly trials and trial method-
ology impact efficacy rates, because patients classified as 
controlled may be classified as uncontrolled at a sequen-
tial time point during the same treatment [2, 14]. This is 
for example illustrated by the difference in biochemical 
response rate between screening and baseline in the phase 
III oral octreotide study [10]. This is also illustrated by the 
variation in levels throughout the trial. In a posthoc analy-
sis presented at the European Congress of Endocrinology, 
Munchen, 2016, the time weighted average response was 
proposed as a more sophisticated way to evaluate response. 
It is calculated by using all available IGF-I and mean GH 
measurements of the core treatment period and by divid-
ing the area under the curve by the total amount of time 
under observation. For example, in the mITT population of 
the phase III trial response rate was 64.9% (98 out of 151 
patients) based on the single time point at the end of core 
treatment, when all available GH and IGF-I levels during 
core treatment were used for evaluation the response rate 
was 71.5%. Sixteen percent of patients were classified dif-
ferently: 17 were responders using the time weighted aver-
age of all measurements but not when the last timepoint 
was evaluated and 7 were responder according to the last 
timepoint but not when evaluated with a time weighted 
average evaluation. Comparable figures were found when 
evaluating the fixed dose population. It was concluded that 
a time weighted average of different sequential values may 
be a more sophisticated measure to reflect chronic control 
in contrast to a single time point when taking into account 
the known variability of GH and IGF-I levels [15].
Systematic evaluation of clinical and (average) biochem-
ical values in clinical practice are also needed to choose and 
monitor best individual treatment options. Recent tools, i.e. 
SAGIT, try to help physicians to optimally score the several 
aspects important for care in acromegaly [16].
It is likely that the patient perspective and patient voice 
will gain more and more attention in the chronic care of 
acromegaly as is in other chronic (endocrine) diseases and 
in view of an individualized approach in management the 
possibility of an effective oral treatment in acromegaly will 
be welcomed as an additional option for a yet unknown 
subset of patients [17].
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